Navigation Links
Tamoxifen Speeds Diagnosis of ER-Negative Breast Cancer
Date:10/7/2008

Study suggests the drug may make tumors easier to spot

TUESDAY, Oct. 7 (HealthDay News) -- A treatment that helps prevent one type of breast cancer in women with an evaluated risk of the disease also appears to help doctors make an earlier diagnosis of another form of breast cancer, a new study reports.

Tamoxifen previously had been shown to reduce the risk of estrogen receptor (ER) positive breast cancer in women at high risk of the disease, but not to affect the chance of developing ER-negative disease.

However, the study by researchers at the University of Texas M.D. Anderson Cancer Center in Houston found that the treatment helped doctors diagnosis women who later developed estrogen receptor (ER) negative breast cancer an average of one year sooner than the same at-risk patients who instead took a placebo.

For the study, 13,388 women at high risk of breast cancer participated in the trial; 174 women were diagnosed with ER-positive tumors and 69 women with ER-negative tumors. The median time to diagnosis for ER-negative disease was 36 months in the placebo group but only 24 months in the tamoxifen group.

The median time to diagnosis for ER-positive disease was similar in the placebo and tamoxifen groups at 43 and 51 months, respectively, which is not statistically different.

It's not clear why the diagnosis time of ER-negative tumors is so different, but the authors hypothesized that the drug may make the tumors more detectable. No evidence was found that tamoxifen altered the growth rate of ER-negative disease.

The study was published online Oct. 7 in the Journal of the National Cancer Institute.

The findings should be investigated further, the researchers concluded.

More information

The National Cancer Institute has more about tamoxifen.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, Oct. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Future hope for patients with breast cancers resistant to tamoxifen
2. New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers
3. Acupuncture relieves hot flushes in breast cancer patients taking tamoxifen
4. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
5. Chemotherapy and tamoxifen reduce risk of second breast cancer
6. Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
7. Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
8. Tamoxifen Helps Treat Bipolar Disorder
9. New Technology Speeds GI Disease Diagnosis
10. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
11. DDT Compound Speeds Breast Cancer Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... surgeon reveals that infants born with severe congenital diaphragmatic hernia have better survival ... born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)...   Zillion Group today announced the ... which specializes in live video consultation. Turning content, ... Zillion enables companies to realize the true potential ... control of their health. Zillion,s ... one-to-one, group and webcast scheduled or on-demand – ...
Breaking Medicine Technology: